WAVE Life Sciences Ltd. $WVE Stake Boosted by Knott David M Jr

Knott David M Jr increased its stake in WAVE Life Sciences Ltd. (NASDAQ:WVE) by 125.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 90,000 shares of the company’s stock after purchasing an additional 50,000 shares during the period. Knott David M Jr owned 0.06% of WAVE Life Sciences worth $659,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. increased its position in WAVE Life Sciences by 20.0% in the second quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock worth $97,607,000 after buying an additional 2,500,000 shares during the period. 683 Capital Management LLC boosted its holdings in shares of WAVE Life Sciences by 4.5% during the second quarter. 683 Capital Management LLC now owns 4,100,000 shares of the company’s stock valued at $26,650,000 after acquiring an additional 175,000 shares during the period. Federated Hermes Inc. grew its position in shares of WAVE Life Sciences by 678,144.7% during the third quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company’s stock worth $27,455,000 after acquiring an additional 3,750,140 shares during the last quarter. Loomis Sayles & Co. L P increased its holdings in shares of WAVE Life Sciences by 35.3% in the 2nd quarter. Loomis Sayles & Co. L P now owns 3,295,700 shares of the company’s stock worth $21,422,000 after acquiring an additional 859,160 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of WAVE Life Sciences by 6.4% in the 2nd quarter. Geode Capital Management LLC now owns 2,759,381 shares of the company’s stock worth $17,938,000 after acquiring an additional 166,982 shares during the period. Institutional investors and hedge funds own 89.73% of the company’s stock.

Insider Buying and Selling at WAVE Life Sciences

In other news, insider Chris Francis sold 33,194 shares of the company’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $15.05, for a total transaction of $499,569.70. Following the completion of the sale, the insider directly owned 61,867 shares of the company’s stock, valued at $931,098.35. This represents a 34.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Plc Gsk purchased 1,470,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average cost of $19.00 per share, for a total transaction of $27,930,000.00. Following the purchase, the insider directly owned 18,245,691 shares in the company, valued at $346,668,129. This represents a 8.76% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold a total of 948,375 shares of company stock valued at $14,112,151 over the last 90 days. 23.98% of the stock is owned by insiders.

WAVE Life Sciences News Summary

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Wedbush raised its price target on WVE to $35 and reiterated an “outperform” rating — a bullish signal implying substantial upside versus the current price and likely supporting buy-side interest. Wedbush price target raise
• Positive Sentiment: HC Wainwright increased near-term EPS estimates across Q1–Q4 2026 and kept a “Buy” rating with a $30 target, signaling improving analyst sentiment on WAVE’s financial outlook. (Research note summarized in market coverage.)
• Positive Sentiment: Wave announced acceptance of a late‑breaking oral presentation for WVE‑006 (GalNAc‑RNA editing) at the American Thoracic Society conference — new data from the RestorAATion‑2 trial (400 mg multidose and 600 mg single‑dose cohorts) will be presented, which could materially move the stock depending on the clinical readout. ATS presentation acceptance
• Neutral Sentiment: Analysts’ long‑range earnings expectations were updated in a report setting FY2029 estimates — useful for modeling but unlikely to drive immediate price moves absent near‑term catalysts. Analyst expectations for FY2029
• Negative Sentiment: A CNBC piece highlighted recent FDA reversals and heightened regulatory scrutiny across biotech (citing multiple denials and reversals), which has increased sector volatility and likely weighed on WVE shares despite company‑specific positives — investors are more sensitive to regulatory risk today. FDA reversals raise sector concerns

WAVE Life Sciences Stock Performance

WAVE Life Sciences stock opened at $13.12 on Friday. The firm has a market cap of $2.47 billion, a price-to-earnings ratio of -10.75 and a beta of -1.77. WAVE Life Sciences Ltd. has a 1 year low of $5.28 and a 1 year high of $21.73. The firm’s 50 day moving average price is $14.00 and its two-hundred day moving average price is $10.94.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). The company had revenue of $17.25 million for the quarter, compared to analyst estimates of $15.68 million. WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%. As a group, equities analysts predict that WAVE Life Sciences Ltd. will post -1.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

WVE has been the subject of a number of analyst reports. Oppenheimer boosted their target price on shares of WAVE Life Sciences from $24.00 to $32.00 and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Wall Street Zen cut WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. UBS Group set a $32.00 price objective on WAVE Life Sciences in a report on Tuesday, December 16th. Cantor Fitzgerald raised their target price on WAVE Life Sciences from $34.00 to $41.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Finally, Bank of America started coverage on WAVE Life Sciences in a research note on Thursday, February 5th. They set a “buy” rating and a $38.00 target price on the stock. Thirteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $33.13.

WAVE Life Sciences Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.